Results 261 to 270 of about 176,756 (350)

Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]

J Ovarian Res
Zhang B, Lv W, Fu Z, Zhou Y, Du J, Yao Q, Qian Q, Bu H.   +7 more
europepmc   +1 more source

Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography

, 2014
Dong Zhou, Wenhua Chu, Jinbin Xu, Lynne A. Jones, Xin Peng, Shihong Li, Delphine L. Chen, Robert H. Mach   +7 more
openalex   +1 more source

Adequacy evaluation of 22‐gauge needle endoscopic ultrasound‐guided tissue acquisition samples and glass slides preparation for successful comprehensive genomic profiling testing: A single institute experience

DEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives This study aimed to evaluate the successful sequencing rate of Foundation One CDx (F1CDx) using small tissue samples obtained with a 22‐gauge needle (22G) through endoscopic ultrasound‐guided fine needle acquisition (EUS‐TA) and to propose guidelines for tissue quantity evaluation criteria and proper slide preparation in clinical ...
Tami Nagatani, Yoji Wani, Masahiro Takatani, Soichiro Fushimi, Hirofumi Inoue, Shinichiro Hori, Kyohei Kai, Hideki Yamamoto, Tetsuya Okazaki, Maki Tanioka, Hiroyuki Okada, Akira Hirasawa   +11 more
wiley   +1 more source

Retraction Note: Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. [PDF]

Sci Rep
Wang YJ, Patel BA, Anreddy N, Zhang YK, Zhang GN, Alqahtani S, Singh S, Shukla S, Kaddoumi A, Ambudkar SV, Talele TT, Chen ZS.   +11 more
europepmc   +1 more source

Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors

, 2004
Alex W. White, Nicola J. Curtin, Brian Eastman, Bernard T. Golding, Zdeněk Hostomský, Suzanne Kyle, Jianke Li, Karen A. Maegley, Donald J. Skalitzky, Stephen E. Webber, Xiaohong Yu, Roger J. Griffin   +11 more
openalex   +1 more source

Patient and Public Involvement Reporting Consistency: Analysis of 24 Clinical Practice Guidelines From 4 Countries

Clinical and Public Health Guidelines, Volume 3, Issue 2, April 2026.
ABSTRACT Objective We compared the reporting of patient and public involvement (PPI) in the development of clinical practice guidelines (CPG) with the guidance regarding PPI in the auspicing organisation's guideline development manual. Methods We examined the PPI guidance provided by seven guideline auspicing organisations from four countries, that ...
Elizabeth Ann Bryant, Rae Thomas, Sharon Lea Sanders   +2 more
wiley   +1 more source

Correction: PARP inhibitors‑associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group. [PDF]

Clin Transl Oncol
Sánchez Cánovas M, López Robles J, García Verdejo FJ, Cacho Lavin D, Olivares H, Garrido Fernández A, Coma Salvans E, Quintanar Verduguez T, Salvador Coloma C, Fernández Garay D, Cumplido JD, Ferrer Pérez AI, Carbó Bagué A, Teigell Muñoz FJ, García López R, Martínez Marin A, Muñoz Martín AJ.   +16 more
europepmc   +1 more source

Clinical Discovery and Molecular Analysis of Two Novel MSH2 Gene Mutations (p.Ala771Gly and p.Val797Gly) in Saudi Colorectal Cancer Patients: Potential Implications for Tumorigenesis

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Colorectal cancer (CRC) is a serious global health problem, ranking first in men and third in women among all cancers worldwide. The genetic basis for CRC remains unclear in most cases; therefore, the present study aimed to investigate the molecular genetic basis of CRC and correlate it with disease outcomes.
Mahmood Rasool, Absarul Haque, Mohammed Alharthi, Tainus Ali, Sajjad Karim, Loubna Siraj Mira, Fahd Al‐Abbasi, Murad Aljiffry, Mohammed Ghunaim, Abdulrahman Sibiany, Peter Natesan Pushparaj   +10 more
wiley   +1 more source

PARPs and PARP inhibitors: molecular mechanisms and clinical applications. [PDF]

Mol Biomed
Wang F, Guo Z, Carr MJ, Shi W.
europepmc   +1 more source